Roivant Sciences Ltd.ROIV

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United Kingdom · roivant.com

Roivant is a commercial-stage biopharmaceutical company that develops and commercializes medicines through nimble subsidiaries known as "Vants". Its pipeline includes LISRAYA (brepocitinib), an FDA-approved JAK1/TYK2 inhibitor for dermatomyositis, IMVT-1402, an anti-FcRn monoclonal antibody for IgG-mediated autoimmune indications, and mosliciguat, an inhaled sGC activator for pulmonary hypertension associated with interstitial lung disease.

Key ratios

FCF / Sales

-9183.5%2026

2025 -2905.2%2024 -2343.6%

Net margin

12984.0%TTM

2024 13294.2%

ROA

-16.5%TTM

2026 -14.4%2025 -10.7%2024 -10.1%

ROE

-8.5%TTM

2026 -7.6%2025 -12.5%2024 112.9%

Revenue growth

-71.6%2026

2025 -11.2%2024 3.8%

Recent news

Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call 2026-09-06 · GlobeNewswire

Track ROIV in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer